Suchergebnisse - "Ahmed, Azazuddin"

PubPharm (15)

1

Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection : A Phase 2 Dose-Ranging Randomized Clinical Trial

enthalten in: JAMA network open | 2022

von Portal-Celhay, C. | Forleo-Neto, E. | Eagan, W. | +127

2

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection : A Randomized Clinical Trial

enthalten in: JAMA | 2022

von O'Brien, M. | Forleo-Neto, E. | Sarkar, N. | +136

UpdateOf: medRxiv. 2021 Sep 18;:. - PMID 34159343

3

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

enthalten in: The New England journal of medicine | 2021

von Weinreich, D. | Sivapalasingam, S. | Norton, T. | +138

4

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

enthalten in: The New England journal of medicine | 2021

von O'Brien, M. | Forleo-Neto, E. | Musser, B. | +134

UpdateOf: medRxiv. 2021 Jun 17;:. - PMID 34159344

5

Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study : A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

enthalten in: Diabetes care | 2020

von Jabbour, S. | Frías, J. | Ahmed, A. | +4

6

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes : The PIONEER 8 Trial

enthalten in: Diabetes care | 2019

von Zinman, B. | Aroda, V. | Buse, J. | +99

7

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy : 52-Week Results of the DURATION-8 Randomized Controlled Trial

enthalten in: Diabetes care | 2018

von Jabbour, S. | Frías, J. | Hardy, E. | +4

8

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial

enthalten in: Diabetes, obesity & metabolism | 2018

von Frías, J. | Hardy, E. | Ahmed, A. | +4

9

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study

enthalten in: Diabetes, obesity & metabolism | 2018

von Jabbour, S. | Frías, J. | Guja, C. | +3

10

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8) : a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

enthalten in: The lancet. Diabetes & endocrinology | 2016

von Frías, J. | Guja, C. | Hardy, E. | +4

CommentIn: Lancet Diabetes Endocrinol. 2016 Dec;4(12 ):963-964. - PMID 27651332